Business Wire

Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, announced today that enrollment for the Phase I clinical study of BAT2022 has ...
Business Wire

Bio-Thera Solutions Reported the Discovery of a Broad-Spectrum SARS-CoV-2 Neutralizing Antibody with Potential to Treat Many Known Variants of COVID-19

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (688177.SH) today announced the discovery of a broad-spectrum SARS-CoV-2 neutralizing antibody with the potential to treat COVID-19. The ...